Desmopressin 30 years in clinical use: A safety review

Current Drug Safety

Volumn 2, Issue 3, 2007, Pages 232-238

  Vande Walle, Johan ^a   Stockner, Mette ^b   Raes, Ann ^a   Nørgaard, Jens P ^b,c  

^a GHENT UNIVERSITY HOSPITAL   (Belgium)

^b International PharmaScience Center   (Denmark)

^c LUND UNIVERSITY   (Sweden)

Author keywords

Desmopressin; Hyponatraemia; Intranasal; Nocturnal polyuria; Oral; Safety

Indexed keywords

ARGIPRESSIN; CARBAMAZEPINE; CHLORPROMAZINE; DESMOPRESSIN; DESMOPRESSIN ACETATE; NONSTEROID ANTIINFLAMMATORY AGENT; PLACEBO; SEROTONIN UPTAKE INHIBITOR; TRICYCLIC ANTIDEPRESSANT AGENT;

ABDOMINAL PAIN; AGE DISTRIBUTION; ANTIDIURESIS; CLINICAL TRIAL; COMORBIDITY; CORRELATION ANALYSIS; DIABETES INSIPIDUS; DIARRHEA; DIZZINESS; DOSE RESPONSE; DRUG ABSORPTION; DRUG BIOAVAILABILITY; DRUG DOSE TITRATION; DRUG EFFICACY; DRUG FORMULATION; DRUG INDICATION; DRUG INDUCED HEADACHE; DRUG SAFETY; DRUG SOLUTION; DRUG SURVEILLANCE PROGRAM; DRUG TOLERABILITY; DRUG USE; DRUG WITHDRAWAL; EPISTAXIS; EVIDENCE BASED MEDICINE; FLUID INTAKE; HEART FAILURE; HUMAN; HYPERTENSION; HYPONATREMIA; MEDLINE; NAUSEA; NOCTURIA; NOCTURNAL ENURESIS; NOSE CONGESTION; OPTIMAL DRUG DOSE; POLYURIA; PRIORITY JOURNAL; PUBLISHING; REVIEW; RHINITIS; RISK REDUCTION; TABLET FORMULATION; VOMITING;

ADVERSE DRUG REACTION REPORTING SYSTEMS; ANTIDIURETIC AGENTS; CLINICAL TRIALS AS TOPIC; DEAMINO ARGININE VASOPRESSIN; HUMANS; HYPONATREMIA; NOCTURIA; NOCTURNAL ENURESIS; RISK FACTORS;

EID: 35348914677     PISSN: 15748863     EISSN: None     Source Type: Journal    
DOI: 10.2174/157488607781668891     Document Type: Review

References (59)

1. Holmes CL, Landry DW, Granton JT. Science review: Vasopressin and the cardiovascular system part 1 - receptor physiology. Crit Care 2003; 7(6): 427-34.
2. Kaufmann JE, Oksche A, Wollheim CB, Gunther G, Rosenthal W, Vischer UM. Vasopressin-induced von Willebrand factor secretion from endothelial cells involves V2 receptors and cAMP. J Clin Invest 2000; 106(1):107-16.
3. Robinson AG. DDAVP in the treatment of central diabetes insipidus. N Engl J Med 1976; 294(10): 507-11.
4. Richardson DW, Robinson AG. Desmopressin. Ann Intern Med 1985; 103(2): 228-39.
5. Norgaard JP, Rittig S, Djurhuus JC. Nocturnal enuresis: an approach to treatment based on pathogenesis. J Pediatr 1989; 114: 705-710.
6. Hjalmas Y, Bengtsson B. Efficacy, safety, and dosing of desmopressin for nocturnal enuresis in Europe. Clin Pediatr (Phila) 1993; Spec No: 19-24.
7. Matthiesen TB, Rittig S, Djurhuus JC, Norgaard JP. A dose titration, and an open 6-week efficacy and safety study of desmopressin tablets in the management of nocturnal enuresis. J Urol 1994; 151: 460-463.
8. Nijman R, Bower W, Ellsworth P, Butler U, Tegkul S, von Gontard A. Diagnosis and management of urinary incontinence and encopresis in childhood. In: Abrams P, Cardozo L, Khoury S, Wein A, Eds, Incontinence. Chpt 16. Plymouth, Plymbridge Distributors Ltd. 2005; Vol 2: 965-1058.
9. Eckford SD, Swami KS, Jackson SR, Abrams PH. Desmopressin in the treatment of nocturia and enuresis in patients with multiple sclerosis. Br J Urol 1994; 74(6): 733-5.
10. Valiquette G, Herbert J, Maede-D'Alisera P. Desmopressin in the management of nocturia in patients with multiple sclerosis. A double-blind, crossover trial. Arch Neurol 1996; 53(12): 1270-5.
11. Lose G, Lalos O, Froeman RM, Van Kerrebroeck P. Efficacy of desmopressin (Minirin) in the treatment of nocturia: a double-blind placebo-controlled study in women. Am J Obstet Gynecol 2003; 189(4): 1106-13.
12. Lose G, Mattiasson A, Walter S, et al. Clinical experiences with desmopressin for long-term treatment of nocturia. J Urol 2004; 172(3): 1021-5.
13. Mattiasson A, Abrams P, Van Kerrebroeck P, Walter S, Weiss J. Efficacy of desmopressin in the treatment of nocturia: a double-blind placebo-controlled study in men. BJU Int 2002; 89(9): 855-62.
14. Abrams P. Cardozo L, Khoury S, Wein A, Eds. Incontinence, 3rd International Consultation on Incontinence. Paris: Health Publication Ltd; 2005.
15. Mannucci PM. Desmopressin (DDAVP) in the treatment of bleeding disorders: the first 20 years. Blood 1997; 90(7): 2515-21.
16. Lethagen S. Desmopressin in mild hemophilia A: indications, limitations, efficacy, and safety. Semin Thromb Hemost 2003; 29(1): 101-6.
17. Dimichele DM, Hathaway WE. Use of DDAVP in inherited and acquired platelet dysfunction. Am J Hematol 1990; 33(1): 39-45.
18. Rado JP. 1-desamino-8-D-arginine vasopressin (DDAVP) concentration test. Am J Med Sci 1978; 275(1):43-52.
19. Åbyholm G, Monn E. Intranasal DDAVP-test in the study of renal concentrating capacity in children with recurrent urinary tract infections. Eur J Pediatr 1979; 130: 149-54.
20. Wambach G, Bönner G, Kleinpass H, et al. Detection of renal impairment in cases of chronic abuse of analgesics by administration of desamino-Darginine vasopressin. Arzneimittelforschung 1989; 39: 387-90.
21. Vestergaard P, Hansen HE. Assessment of renal concentrating ability in lithium-treated patients. Acta Psychiatr Scand 1980; 61: 152-6.
22. European Medicines Agency (EMEA) [homepage on the internet]. London: European Medicines Committee For Medicinal Products For Human Use. Reflection Paper: Formulations of Choice for the Paediatric Population. [updated 2005 Jun 23]. Available from: http://www.emea.eu.int/pdfs/human/ peg/19481005en.pdf
23. Hjalmas K, Arnold T, Bower W, et al. Nocturnal enuresis: an international evidence based management strategy. J Urol 2004; 171(6 Pt 2): 2545-61.
24. Bradbury MG, Meadow SR. Combined treatment with enuresis alarm and desmopressin for nocturnal enuresis. Acta Paediatr 1995; 84(9): 1014-8.
25. Marschall-Kehrel AD, Murtz G, Kramer G, Junemann KP, Madersbacher H, Hjalmas K. A suggested treatment algorithm in nocturnal] enuresis with emphasis on partial responders. Urologe A 2004; 43: 795-802.
26. Glazener CM, Evans JH. Desmopressin for nocturnal enuresis in children. Cochrane Database Syst Rev 2002; 3: CD002112.
27. van Kerrebroeck PE. Experience with the long-term use of desmopressin for nocturnal enuresis in children and adolescents. BJU Int 2002; 89(4): 420-5.
28. Wolfish NM, Barkin J, Gorodzinsky F, Schwarz R. The Canadian Enuresis Study and Evaluation - short - and long-term safety and efficacy of an oral desmopressin preparation. Scand J Urol Nephrol 2003; 37(1): 22-7.
29. Forsythe WI, Redmond A. Enuresis and spontaneous cure rate. Study of 1129 enuretics. Arch Dis Child 1974; 49(4): 259-63.
30. Stenberg A, Lackgren G. Desmopressin tablets in the treatment of severe nocturnal enuresis in adolescents. Pediatrics 1994; 94(6 Pt 1): 841-6.
31. Uygur MC, Ozgu IH, Ozen H, et al. Long-term treatment of nocturnal enuresis with desmopressin intranasal spray. Clin Pediatr (Phila) 1997; 36(8): 455-9.
32. Miller K, Goldberg S, Atkin B. Nocturnal enuresis: experience with long-term use of intranasally administered desmopressin. J Pediatr 1989; 114(4 Pt 2): 723-6.
33. Riccabona M, Oswald J, Glauninger P. Long-term use and tapered dose reduction of intranasal desmopressin in the treatment of enuretic children. Br J Urol 1998; 81(Suppl 3): 24-5.
34. Tullus K, Bergstrom R, Fosdal I, Winnergard I, Hjalmas K. Efficacy and safety during long-term treatment of primary monosymptomatic nocturnal enuresis with desmopressin. Swedish Enuresis Trial Group. Acta Paediatr 1999; 88(11): 1274-8.
35. Glazener CM, Evans JH, Peto RE. Treating nocturnal enuresis in children: review of evidence. J Wound Ostomy Continence Nurs 2004; 31(4):223-34.
36. Lyon C, Schnall J. What is the best treatment for nocturnal enuresis in children? J Fam Pract 2005; 54(10): 905-6, 909.
37. Lackgren G, Lilja B, Neveus T, Stenberg A. Desmopressin in the treatment of severe nocturnal enuresis in adolescents - a 7-year follow-up study. Br J Urol 1998; 81(Suppl 3): 17-23.
38. Del Gado R, Del Gaizo D, Cennamo M, Auriemma R, Del Gado G, Verni M. Desmopressin is a safe drug for the treatment of enuresis. Scand J Urol Nephrol 2005; 39(4): 308-12.
39. Fjellestad-Paulsen A, Wille S, Harris AS. Comparison of intranasal and oral desmopressin for nocturnal enuresis. Arch Dis Child 1987; 62(7): 674-7.
40. Matthiesen TB, Rittig S, Djurhuus JC, Norgaard JP. A dose titration, and an open 6-week efficacy and safety study of desmopressin tablets in the management of nocturnal enuresis. J Urol 1994; 151(2): 460-3.
41. Skoog SJ, Stokes A, Turner KL. Oral desmopressin: a randomized double-blind placebo controlled study of effectiveness in children with primary nocturnal enuresis. J Urol 1997; 158(3 Pt 2): 1035-40.
42. Janknegt RA, Zweers HM, Delaere KP, Kloet AG, Khoe SG, Arendsen HJ. Oral desmopressin as a new treatment modality for primary nocturnal enuresis in adolescents and adults: a double-blind, randomized, multicenter study. Dutch Enuresis Study Group. J Urol 1997; 157(2): 513-17.
43. Schulman SL, Stokes A, Salzman PM. The efficacy and safety of oral desmopressin in children with primary nocturnal enuresis. J Urol 2001; 166(6): 2427-31.
44. Robson WL, Norgaard JP, Leung AK. Hyponatremia in patients with nocturnal enuresis treated with DDAVP. Eur J Pediatr 1996; 155(11): 959-62.
45. Schrier RW. The patient with hyponatraemia or hypernatremia. In: Manual of Nephrology. Philadelphia, Lippincott Williams and Wilkins 2000; 21-6.
46. Miller JH, Shock NW. Age differences in the renal tubular response to anti-diuretic hormone. J Gerontol 1953; 8(4): 446-50.
47. Miller M. Nocturnal polyuria in older people: pathophysiology and clinical implications. J Am Geriatr Soc 2000; 48(10): 1321-9.
48. Bauer JH. Age-related changes in the renin-aldosterone system, physiological effects and clinical implications. Drugs Ageing 1993; 3(3): 238-45.
49. Abrams P, Mattiasson A, Lose GR, Robertson GL. The role of desmopressin in the treatment of adult nocturia. BJU Int 2002; 90(Suppl 3): 32-6.
50. Rembratt A, Riis A, Norgaard JP. Desmopressin treatment in nocturia; an analysis of risk factors for hyponatremia. Neurourol Urodyn 2006; 25(2): 105-9.
51. Weatherall M. The risk of hyponatremia in older adults using desmopressin for nocturia: a systematic review and meta-analysis. Neurourol Urodyn 2004; 23(4): 302-5.
52. Callreus T, Ekman E, Andersen M. Hyponatremia in elderly patients treated with desmopressin for nocturia: a review of a case series. Eur J Clin Pharmacol 2005; 61(4): 281-4.
53. Thumfart J, Roehr CC, Kapelari K, Querfeld U, Eggert P, Muller D. Desmopressin associated symptomatic hyponatremic hypervolemia in children. Are there predictive factors? J Urol 2005; 174(1): 294-8.
54. Kennedy D, Goldman S, Lilie R. Spontaneous adverse drug reactions in the United States. In: Strom BL Eds, Pharmacoepidemiology, 3rd edition. Chichester, John Wiley & Sons. 2000; 151-74.
55. Council for International Organizations of Medical Sciences (CIOMS). Guidelines for Preparing Core Clinical-Safety Information on Drugs (Second edition) (Report of CIOMS Working Group III & V) 1998. ISBN 92 9036 070 4.
56. Vande Walle J, Bogaert GA, Mattsson S, et al. A new fast-melting oral formulation of desmopressin (Minirin® Melt): a pharmacodynamic study in children with primary nocturnal enuresis. BJU Int 2006; 97(3): 603-9.
57. Dehoorne JL, Raes AM, Van Laecke E, Hoebeke P, Vande Walle JG. DDAVP-toxicity due to prolonged half-life in 18 patients with nocturnal enuresis. J Urol 2006; 176(2): 754-7.
58. Robson WLM, Leung AKC, Norgaard JP. The comparative safety of oral versus intranasal desmopressin in the treatment of children with nocturnal enuresis. J Urol 2007; In press.
59. Robson WL, Leung AK. Side effects and complications of treatment with desmopressin for enuresis. J Natl Med Assoc 1994; 86(10): 775-8.